How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Genome Assembly Service Market
- By Technology Platform: Short-read Sequencing, Long-read Sequencing, Synthetic Long-read Sequencing, Optical Mapping, Chromosome Conformation Capture (Hi-C)
- By Assembly Type: De novo Assembly, Reference-guided Assembly, Hybrid Assembly
- By End-user: Academic and Research Institutes, Biopharmaceutical Companies, Agricultural Biotechnology Firms, Clinical and Diagnostic Laboratories, Contract Research Organizations (CROs)
- By Application: Human Genome Assembly, Microbial Genome Assembly, Plant Genome Assembly, Animal Genome Assembly, Metagenomic Assembly
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Short-read Sequencing leads By Technology Platform at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.167 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.175 →
Full report · locked preview
Everything inside the Genome Assembly Service Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Technology Platform 5
Assembly Type 3
End-user 5
Application 5
Companies profiled
Illumina Inc.
BGI Group
Thermo Fisher Scientific Inc.
Pacific Biosciences of California Inc.
Oxford Nanopore Technologies
Genewiz (a Brooks Life Sciences company)
Eurofins Scientific
Macrogen Inc.
Novogene Corporation
Genoox
DNAnexus Inc.
Gene by Gene Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BGI Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pacific Biosciences of California Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Oxford Nanopore Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Genewiz (a Brooks Life Sciences company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Macrogen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novogene Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Genoox
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →DNAnexus Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Gene by Gene Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Fulgent Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Q2 Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Personalis
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,866M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Short-read Sequencing50.6
- Long-read Sequencing5.9
- Synthetic Long-read Sequencing12.8
- Optical Mapping14.9
- Chromosome Conformation Capture (Hi-C)15.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$400.9M → $658.3M · 6.4%
Europe$279.4M → $420.6M · 5.2%
Asia Pacific$255.1M → $420.8M · 6.5%
Latin America$157.9M → $226.6M · 4.6%
Middle East and Africa$121.5M → $194.2M · 6.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.462026
5.472027
5.482028
5.502029
5.522030
5.522031
5.542032
5.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Illumina Inc.21.6
- BGI Group9.8
- Thermo Fisher Scientific Inc.12.7
- Pacific Biosciences of California Inc.13.4
- Oxford Nanopore Technologies9.7
- Genewiz (a Brooks Life Sciences company)4.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology Platform39.6%
Assembly Type20.6%
End-user18.7%
Application21.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe21.9
- Asia Pacific21.9
- Latin America11.8
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | 74 | 76 | 84 | 78 | 82 | 85 | 80 |
| BGI Group | 88 | 91 | 85 | 71 | 72 | 83 | 82 |
| Thermo Fisher Scientific Inc. | 70 | 78 | 82 | 68 | 88 | 81 | 78 |
| Pacific Biosciences of California Inc. | 57 | 77 | 76 | 58 | 66 | 78 | 69 |
| Oxford Nanopore Technologies | 68 | 65 | 67 | 53 | 58 | 57 | 61 |
| Genewiz (a Brooks Life Sciences company) | 54 | 63 | 62 | 54 | 62 | 66 | 60 |
| Eurofins Scientific | 59 | 62 | 49 | 51 | 55 | 53 | 55 |
| Macrogen Inc. | 40 | 48 | 56 | 56 | 49 | 57 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Illumina Inc.
- BGI Group
- Thermo Fisher Scientific Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Illumina Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| BGI Group | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific Inc. | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Pacific Biosciences of California Inc. | − | ◐ | ✓ | ◐ | ◐ | ◐ |
| Oxford Nanopore Technologies | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Genewiz (a Brooks Life Sciences company) | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Eurofins Scientific | − | ◐ | ◐ | − | − | − |
| Macrogen Inc. | − | − | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BGI Group82
2Illumina Inc.80
3Thermo Fisher Scientific Inc.78
4Pacific Biosciences of California Inc.69
5Oxford Nanopore Technologies61
6Genewiz (a Brooks Life Sciences company)60
7Eurofins Scientific55
8Macrogen Inc.51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Illumina Inc.BGI GroupThermo Fisher Scientific Inc.
Challenger1
Strong scale, closing on the leaders.
Pacific Biosciences of California Inc.
Contender2
Focused players with pockets of strength.
Oxford Nanopore TechnologiesGenewiz (a Brooks Life Sciences company)
Niche2
Specialists in a single segment or region.
Eurofins ScientificMacrogen Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology Platform in North America, then scale across Genome Assembly Service Market — a $299M beachhead inside a $4.18B market.
Beachhead (SOM)$299Mobtainable near-term
Serviceable (SAM)$1.62Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Short-read Sequencing
Best fit — highest urgency & budget in Technology Platform.
Economic buyer75 fit
Long-read Sequencing
Strong fit — clear ROI and a fast path to value.
End user64 fit
Synthetic Long-read Sequencing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology Platform in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Assembly Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-user
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Technology Platform leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Genome Assembly Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified21%
Evaluation14%
Closed-won6%
$10.1KCAC
$56KLTV
5.5:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Genome Assembly Service Market is a durable-growth opportunity — $9.66B by 2033, compounding at 7.5%.
TAM · 2025$5.43Btoday
TAM · 2033$9.66Bforecast
CAGR7.5%2027–2033
Cumulative$66.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.66BTotal addressable market
SAM$4.05BServiceable available market
SOM$684MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.5% CAGR
Demand compounds through 2033, outpacing GDP across Technology Platform.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology Platform moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.66BLarge & growingTAM by 2033 at 7.5% CAGR
$4.05BServiceable nowreachable with today’s model
$684MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.54BBear4.9% CAGR
$9.66BBase7.5% CAGR
$12.4BBull9.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Assembly Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Genome Assembly Service Market — a $10.4B market by 2033. Plan: grow share from 5.8% to 12.0%.
Market size · 2033$10.4Btotal addressable
Market CAGR10.1%2027–2033
Target share12.0%from 5.8% today
Revenue ambition$1.25Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 12.0% | On track |
| Revenue | $621M | $1.25B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 34.4% | 45.4% | On track |
| Customer retention | 87.5% | 96.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology Platform
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Assembly Type capability
A defensible second engine — invest in Assembly Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology Platform share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Assembly Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $183M capacity & capability investment
- Greenlight bolt-on M&A in Assembly Type
- Authorise North America expansion plan
- Fund R&D program for Technology Platform leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Genome Assembly Service Market conversation — a $1.07B market you can size, segment and defend in minutes.
Market size · 2033$1.07Btotal opportunity
Growth4.5%CAGR to 2033
Addressable buyers1,332+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology Platform
Goal Grow share in Technology Platform
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 3 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Illumina Inc.BGI GroupThermo Fisher Scientific Inc.Pacific Biosciences of California Inc.Oxford Nanopore TechnologiesGenewiz (a Brooks Life Sciences company)Eurofins ScientificMacrogen Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Genome Assembly Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Genome Assembly Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Genitourinary Prosthetics Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportGenitourinary Cancers Treatment Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportGenital Warts Treatment Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportGenital Herpes Vaccine Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportGenital Herpes Research and Development Pipeline Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportGeniposidic Acid Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportGene Vector Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportGene Transfer Instrument Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGenetic Virus Vector Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportGenetic Toxicology Testing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportGenetic Toxicology Market
Market size, share, segmentation and regional forecast.
$920M market · 2025 base year
View reportGenetic Toxicity Impurity Testing Services Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.